Emerging Therapies for the Management of Castration- Sensitive Prostate Cancer

May 21, 2021 | 3:00 - 4:00 PM EDT

This educational activity is jointly provided by AXIS Medical Education and the Association of Community Cancer Centers (ACCC).

This educational activity is supported by independent grants from Astellas and Pfizer, Inc.

Target Audience

The target audience for this initiative includes medical oncologists, urologic oncologists, urologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals (HCPs) involved in treating patients with prostate cancer.

Overview

Prostate cancer is the second most common cancer, after skin cancer, among men. It is the second leading cause of cancer death in the United States. This year, it is estimated that about 174,650 men in the United States will be diagnosed with prostate cancer and 31,620 men will die from this disease. Androgen deprivation therapy (ADT) aimed at lowering the level of androgens, is the standard of care for men with advanced prostate cancer. Newly diagnosed metastatic disease that has spread to other parts of the body and still responds to testosterone suppression therapy is called metastatic castration-sensitive prostate cancer (mCSPC). Androgen receptor inhibitors are currently being investigated in combination with ADT given the knowledge that deeper androgen signal inhibition results in further improved outcomes in mCSPC. With the recent drug approvals and updates to clinical practice guidelines, several knowledge, competence and performance gaps exist in the optimal management of mCSPC among oncology practitioners. Participants from previous Association of Community Cancer Centers (ACCC) educational programs revealed transitions of care, including communication between the numerous healthcare settings (52%), side effect management (45%), and keeping current on the latest treatment modalities (29%) as among the most commonly encountered challenges for practitioners.

This education activity will provide guidance on the optimal management of mCSPC to oncologists, urologists, oncology advanced practitioners and other members of the multidisciplinary cancer care team. The educational program will address some of the challenges in optimal sequencing of care in mCSPC and will provide an opportunity to discuss with leading oncology experts and colleagues how new research clinical updates can be translated into new patient care strategies.

Learning Objectives

At the end of this educational activity, participants should be able to:

  1. Describe current and emerging treatment options in mCSPC.
  2. Employ strategies for optimal management of treatment-related adverse events experienced by patients treated for mCSPC.
  3. Examine solutions for improving coordination and communication within the multidisciplinary cancer care team and with patients/caregivers to improve outcomes for patients with mCSPC.

Faculty

Pedro Barata, MD, MSc
Assistant Professor, Deming Department of Medicine, Division of Hematology/Oncology, Genitourinary Cancers, Tulane University

Lisa M. Holle, PharmD, BCOP, FHOPA
Associate Clinical Professor, UConn School of Pharmacy
Associate Professor, UConn School of Medicine

 

ACCREDITED CONTINUING EDUCATION

Accreditation Statement

Jointly Accredited Provider LogoIn support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and ACCC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE LogoThis activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Credit Designation for Physicians
AXIS Medical Education designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hour of continuing pharmacy education credit JA4008106-9999-21-021-L01-P.

Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

AXIS Contact Information
For information about the accreditation of this program please contact AXIS at info@axismeded.org.

Disclosure of Conflicts of Interest

AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is t producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.

AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by  staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:

 

Name of Faculty or Presenter/Planner Reported Financial Relationship
   

Pedro Barata, MD, MSc

Consultant (Institutional): Astellas, Dendreon, Eisai, EMD Serono, Pfizer, Inc., and Seattle Genetics

Contracted Research (Institutional): AstraZeneca

Research Grant (Institutional): BlueEarth Diagnostics

Speaker's Bureau: Bayer and Caris

Lisa M. Holle, PharmD, BCOP, FHOPA 

Nothing to disclose

 

The directors, planners, managers and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months:

 

Name of Planner/Manager/Reviewer Reported Financial Relationship
   

Archana Ajmera, MSN, ANP-BC, AOCNP

Consultant: Janssen

Eric Castle, MD

Nothing to disclose

Marilyn Haas, PhD, RN, CNS, ANP-BC

Nothing to disclose

Lisa M Holle, PharmD, BCOP, FHOPA

Nothing to disclose

Dee Morgillo, MEd., MT (ASCP) CHCP

Nothing to disclose

Mary Stanley, MSW, PMP

Nothing to disclose

 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

  • Attend/participate in the educational activity and review all course materials.
  • Complete the CE Declaration form online by 11:59 PM ET on June 21, 2021. Instructions will be provided. If you do not enter the online portal by the above date, you will not be able to retrieve your statement of participation.  
  • Upon successful completion of the online form, your statement of completion will be presented to you to print. Pharmacists: your record will be automatically uploaded to CPE Monitor.

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
vah-o.com
Email Us